Search - tctmd.com

Displaying 101 - 112 of 112

Sort: Relevancy | Date

News Daily News

Patient-Level Pooled Analysis Supports Bivalirudin Use in Primary PCI

Yael L. Maxwell

January 12, 2015

News Daily News

Meta-Analysis: Worse Clinical Outcomes But Less Bleeding With Bivalirudin in PCI

Todd Neale

August 20, 2014

News Daily News

Prasugrel Noninferior to Ticagrelor in STEMI, but Both Require Hours to Achieve Effect

Yael L. Maxwell

May 13, 2013

News Conference News ESC 2012

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

August 26, 2012

News Daily News

First-Year Stent Thombosis Risk High—and Dangerous—in ACS Patients

October 31, 2011

News Daily News

Bivalirudin Decreases Bleeding Regardless of Heparin Anticoagulation Level

Yael L. Maxwell

October 13, 2011

News Daily News

Interruption of Antiplatelet Therapy Unnecessary for Tooth Extraction

July 27, 2011

News Daily News

Apixaban Increases Major Bleeding in High-Risk ACS Patients

Jason Kahn

July 25, 2011

News Daily News

Antithrombin Plus Preloading with Clopidogrel May Reduce Stent Thrombosis

L.A. McKeown

April 15, 2011

Video

» Interview

TICO-STEMI: A Randomized Trial of Ticagrelor Monotherapy vs Ticagrelor With Aspirin in STEMI

October 14, 2020

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Roxana Mehran About TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor Plus Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

September 27, 2019

Video

» Interview

ACC 2019: GLASSY: Impact of Ticagrelor Monotherapy Beyond One Month Versus Conventional Therapy On Adjudicated Ischemic And Bleeding Endpoints Following Drug Eluting Sent Implantation. Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY

March 18, 2019

Advertisement

Patient-Level Pooled Analysis Supports Bivalirudin Use in Primary PCI

Meta-Analysis: Worse Clinical Outcomes But Less Bleeding With Bivalirudin in PCI

Prasugrel Noninferior to Ticagrelor in STEMI, but Both Require Hours to Achieve Effect

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

First-Year Stent Thombosis Risk High—and Dangerous—in ACS Patients

Bivalirudin Decreases Bleeding Regardless of Heparin Anticoagulation Level

Interruption of Antiplatelet Therapy Unnecessary for Tooth Extraction

Apixaban Increases Major Bleeding in High-Risk ACS Patients

Antithrombin Plus Preloading with Clopidogrel May Reduce Stent Thrombosis

TICO-STEMI: A Randomized Trial of Ticagrelor Monotherapy vs Ticagrelor With Aspirin in STEMI

Dr. C. Michael Gibson Talks With Dr. Roxana Mehran About TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor Plus Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

ACC 2019: GLASSY: Impact of Ticagrelor Monotherapy Beyond One Month Versus Conventional Therapy On Adjudicated Ischemic And Bleeding Endpoints Following Drug Eluting Sent Implantation. Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content